IV gamitrinib study for advanced cancers needing new options
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests how safe IV gamitrinib is and how the body processes it in people with advanced cancers that can’t be controlled by standard treatment. It may also help researchers learn the best dose and whether it has signs of anti-cancer activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced cancer that’s not responding to standard treatment, or there is no standard treatment available
- You’re 18 years or older and can do day-to-day activities (performance status 0 to 2)
- Your blood counts and organ function (kidneys, liver, etc.) must meet lab thresholds—your care team will check recent labs
- If you’re in the dose expansion part: you must have measurable tumor spots that can be tracked on scans, and you must be willing to get required needle biopsies (before treatment and during treatment)
- You must have no symptom-causing brain metastases, and if you had brain treatment before, it must be finished at least 28 days ago and you cannot be on steroid medicines for it
- You cannot be in another treatment study, you need to be off prior cancer treatments for the required washout time, and you must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs, Simmitinib and SG001, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to find out if this combination is safe and effective.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.